美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Nasdaq Biotechnology ETF

34.69

-0.4365-1.24%

盤後：34.710.0207+0.06%19:30 EDT

成交量：2.55萬

成交額：88.53萬

市值：9,643.63萬

市盈率：- -

高：35.13

開：35.13

低：34.63

收：35.13

52周最高：36.84

52周最低：23.42

股本：278.00萬

流通股本：278.00萬

量比：1.14

換手率：0.92%

股息：0.26

股息率：0.74%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

DELPHI‑305 三期臨床試驗達到主要終點。

Tozorakimab在OBERON和TITANIA兩項Ⅲ期臨床試驗中，在降低慢阻肺病急性加重方面均顯示出統計學和臨床意義上的顯著改善

兩項驗證性試驗迎突破性結果！阿斯利康Tozorakimab再傳好消息

更正-安進與阿斯利康聯合研發的抗癌藥物組合在晚期臨床試驗中達到了主要生存目標

安進Phase 3 Dellphi-305研究重大突破：總生存期獲益顯著優於度伐利尤單抗單藥治療

Imdelltra®聯合Imfinzi®在一線廣泛期小細胞肺癌中展現里程碑式總生存期改善

BMO下調安進及BioNTech評級至「與大市同步」

苑東生物：公司將於9月16日參加科創板2026年半年度創新藥行業集體業績説明會

禮邦醫藥-B(09637)：AP308治療IgA腎病的新藥臨床試驗申請獲美國食品藥品監督管理局批准

美股盤前｜英特爾、甲骨文升逾4%；諾華重挫12%，IONIS下跌10%；阿斯麥新一代EUV光刻機獲台積電和三星使用承諾

老虎资讯综合

AI 製藥迎來價值兑現期，創新藥產業打開全新增長空間

独角兽智库

PHARVARIS的3期臨床試驗達到全部主要及次要終點。

石藥集團：SYH2083滴眼液獲臨床試驗批准

膽固醇藥物臨床試驗受挫，數十億美元研發競賽蒙上陰影

环球市场播报

諾華試驗受挫且BMO下調評級，安進股價下跌

復星醫藥(600196.SH)子公司FXS5626片獲臨床試驗批准

盤前異動：安進、耐克、Bloom Energy 等個股受關注

美股異動｜安進盤前跌5.4%，諾華同靶點藥物III期臨床失敗，Lp(a)賽道遭重創

製藥巨頭諾華股價大跌近10%，遭遇三項藥物臨床試驗受挫

环球市场播报

安進股價盤前下跌5.4%；競爭對手諾華的膽固醇藥物後期臨床試驗失敗。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/IBBQ/news?page=9"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.6893,"timestamp":1789761600000,"preClose":35.1258,"halted":0,"volume":25488,"hourTrading":{"tag":"盘后","latestPrice":34.71,"preClose":34.6893,"latestTime":"19:30 EDT","volume":16,"amount":555.1565,"timestamp":1789774205753,"change":0.0207,"changeRate":0.000597,"amplitude":0},"delay":0,"changeRate":-0.012426763233862154,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"休市中","change":-0.4365,"latestTime":"09-18 16:00:00 EDT","open":35.13,"high":35.13,"low":34.6296,"amount":885294.380736,"amplitude":0.014246,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":35.1258,"sharesOutstanding":2520001,"nav":35.11978,"aum":96412871.83,"dividendRate":0.007406,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":34.71,"preClose":34.6893,"latestTime":"19:30 EDT","volume":16,"amount":555.1565,"timestamp":1789774205753,"change":0.0207,"changeRate":0.000597,"amplitude":0},"volumeRatio":1.1394951737825971,"impliedVol":0.0457,"impliedVolPercentile":0.0199},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.1394951737825971,"shares":2780001,"dividePrice":0.2569,"high":35.13,"amplitude":0.014246,"preClose":35.1258,"low":34.6296,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.6893,"eps":0,"divideRate":0.007406,"volume":25488,"delay":0,"ttmEps":0,"open":35.13,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":34.472,"twentyDayClose":35.8,"sixtyDayClose":31.2119},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-09-21","symbol":"IBBQ","amount":0.23037,"announcedDate":"2026-09-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-21","defaultRemindTime":1789997400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-25","payableDate":"2026-09-21","currency":"USD","dateTimestamp":1789963200000,"payDate":"2026-09-25"},{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:9,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665373053","title":"DELPHI‑305 三期臨床試驗達到主要終點。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665373053","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665373053?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:19","pubTimestamp":1788873564,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","IBBJ","IBBQ","MDTX","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665968376","title":"Tozorakimab在OBERON和TITANIA兩項Ⅲ期臨床試驗中，在降低慢阻肺病急性加重方面均顯示出統計學和臨床意義上的顯著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2665968376","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665968376?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:18","pubTimestamp":1788873480,"startTime":"0","endTime":"0","summary":"OBERON和TITANIA两项Ⅲ期试验的结果令人鼓舞，证实tozorakimab在广泛患者人群中均能降低急性加重风险，有望帮助患者摆脱反复急性加重的困扰，获得全新的治疗选择。Tozorakimab 是首个在广泛慢阻肺病患者人群中显示出减少气道黏液栓堵塞作用的生物制剂3。Tozorakimab总体耐受性和安全性良好，唯一报告的药物不良反应为注射部位反应1,2。目前，tozorakimab已在欧盟、中国等主要市场进入上市许可审评阶段，用于治疗慢性阻塞性肺疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5042444_ZH42444_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5042444_ZH42444_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1829250122.USD","LU2456880835.USD","LU2468319806.SGD","LU2237443549.SGD","LU0289739699.SGD","LU2237443978.SGD","LU0320765992.SGD","IBBQ","LU2237443622.USD","LU0432979614.USD","LU0889565916.HKD","LU2237443465.HKD","LU0708994859.HKD","LU2462157665.USD","LU2237443382.USD","BK4585","LU1267930573.SGD","BK4588","MDTX","BK4007","AZNH","LU2089984988.USD","LU0029864427.USD","LU2237443895.HKD","BMED","LU0310800379.SGD","LU0109394709.USD","IBBJ","AZN","LU2236285917.USD","BK4568","LU2417539215.USD","LU0128525929.USD","PSYK","IE00B3T34201.USD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665137530","title":"兩項驗證性試驗迎突破性結果！阿斯利康Tozorakimab再傳好消息","url":"https://stock-news.laohu8.com/highlight/detail?id=2665137530","media":"上观新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665137530?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:14","pubTimestamp":1788873273,"startTime":"0","endTime":"0","summary":"慢性阻塞性肺疾病候选药物Tozorakimab再度传来好消息：其在最新两项验证性试验中都展示出了突破性结果，有望为全球数百万接受标准吸入治疗后仍面临急性加重风险的患者带来新的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083868309733.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083868309733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBQ","BEZ","BEX","BEC","BEG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665732793","title":"更正-安進與阿斯利康聯合研發的抗癌藥物組合在晚期臨床試驗中達到了主要生存目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2665732793","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665732793?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:14","pubTimestamp":1788873260,"startTime":"0","endTime":"0","summary":"阿斯利康抗癌药物组合在晚期临床试验中达到主要生存目标路透9月8日-阿斯利康（AstraZeneca）AZN.L周二表示，其抗癌药物Imfinzi与安进（Amgen）的AMGN.O靶向免疫疗法Imdelltra联合使用，在一项晚期临床试验中，显著提高了广泛期小细胞肺癌一线治疗患者的总生存期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4S450114:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0868494617.USD","TBXU","LU0957799991.USD","BBH","LU1084165304.USD","PJP","LU2279689827.SGD","LU0969580561.USD","LU0526926950.USD","BIB","AZN.UK","BK4139","IBB","LU0029864427.USD","LU0545039389.USD","LU0058720904.USD","LU2242652126.USD","LU0920783379.SGD","LU0882574055.USD","PBE","IE0034235188.USD","LU0289739699.SGD","LU0077335932.USD","LU1863844749.USD","LU1046234339.USD","BK4599","LU0889566641.SGD","LU1487256676.USD","LU1880407132.USD","LU0997586515.USD","LU1829250122.USD","03165","LU1003076772.USD","AMGN","LU0661504455.SGD","LU0784383803.USD","LU0109394709.USD","LU1481599808.USD","LU0827474353.SGD","LU2091194634.USD","IBBQ","LU0122379950.USD","LU2355687059.USD","LU0203347892.USD","LU1023059063.AUD","LU2433249047.HKD","LU1170363599.USD","LU1923622614.USD","LU1061106388.HKD","LU2237443465.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115495471","title":"安進Phase 3 Dellphi-305研究重大突破：總生存期獲益顯著優於度伐利尤單抗單藥治療","url":"https://stock-news.laohu8.com/highlight/detail?id=1115495471","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115495471?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:07","pubTimestamp":1788872830,"startTime":"0","endTime":"0","summary":"安进公司宣布，其Phase 3 Dellphi-305临床研究取得重大成果——与度伐利尤单抗单独用药相比，该疗法在总生存期上展现出显著且具有临床意义的改善。这一里程碑式的发现，无疑为肿瘤治疗领域注入了新的活力与希望。尽管完整的详细数据尚未全面披露，但安进方面表示，其临床意义及安全性特征将在即将召开的重大学术会议上进行详尽报告。安进公司并未止步于此。随着研发管线的持续推进，安进正逐步兑现其以创新疗法攻克严重疾病的承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU2468319806.SGD","LU1061106388.HKD","LU1057294990.SGD","BK4581","PBE","TBXU","LU0320765992.SGD","IE0002141913.USD","LU1023059063.AUD","LU2242646821.SGD","IBBQ","IBB","BK4139","AMGN","LU0289739699.SGD","SG9999001440.SGD","IE00B2B36J28.USD","BK4599","BK4534","LU2242652126.USD","LU0868494617.USD","PJP","BK4585","IE00BJJMRZ35.SGD","IE0009355771.USD","LU0109394709.USD","BK4566","BK4533","IE00B4R5TH58.HKD","LU2112291526.USD","IE00BFTCPJ56.SGD","BIB","LU0058720904.USD","LU1571399168.USD","LU2089984988.USD","LU0122379950.USD","IE00BJT1NW94.SGD","BK4588","BBH","LU1983299246.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109517247","title":"Imdelltra®聯合Imfinzi®在一線廣泛期小細胞肺癌中展現里程碑式總生存期改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1109517247","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109517247?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:04","pubTimestamp":1788872687,"startTime":"0","endTime":"0","summary":"Imdelltra®与Imfinzi®的联合疗法，于一线广泛期小细胞肺癌治疗领域，取得了具有划时代意义的总生存期提升。这一突破性进展，不仅为患者带来了新的曙光，也重塑了该领域的治疗格局。从数据层面观察，联合治疗方案的生存获益尤为显著，堪称里程碑式的成就。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","PBE","BK4599","IE0002141913.USD","IE00B4R5TH58.HKD","BK4566","LU2112291526.USD","LU2242646821.SGD","LU1571399168.USD","IBBQ","LU1983299246.USD","BIB","LU0889565916.HKD","IE00B2B36J28.USD","LU2468319806.SGD","BBH","LU0058720904.USD","LU1057294990.SGD","LU2089984988.USD","BK4588","LU2242652126.USD","BK4533","IE0009355771.USD","LU1061106388.HKD","LU0289739699.SGD","BK4139","IE00BJJMRZ35.SGD","AMGN","LU0109394709.USD","IBB","IE00BFTCPJ56.SGD","LU0868494617.USD","TBXU","IE00BJT1NW94.SGD","LU0320765992.SGD","BK4585","BK4534","LU1023059063.AUD","BK4581","PJP","SG9999001440.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665387373","title":"BMO下調安進及BioNTech評級至「與大市同步」","url":"https://stock-news.laohu8.com/highlight/detail?id=2665387373","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665387373?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:59","pubTimestamp":1788872377,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4585","BK4534","BK4588","LU2468319806.SGD","LU0109394709.USD","IE0002141913.USD","PJP","IE00B2B36J28.USD","LU0122379950.USD","LU2242646821.SGD","TBXU","LU1057294990.SGD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU1571399168.USD","LU1023059063.AUD","AMGN","LU0058720904.USD","IBB","LU2242652126.USD","PBE","LU2112291526.USD","IBBQ","BK4599","BK4566","LU2089984988.USD","IE00BFTCPJ56.SGD","LU0868494617.USD","BBH","LU0289739699.SGD","LU0320765992.SGD","LU1061106388.HKD","BK4581","LU1983299246.USD","SG9999001440.SGD","BK4533","LU0889565916.HKD","IE00B4R5TH58.HKD","BIB","BK4139","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378020","title":"苑東生物：公司將於9月16日參加科創板2026年半年度創新藥行業集體業績説明會","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378020","media":"证券日报 ","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378020?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:16","pubTimestamp":1788869760,"startTime":"0","endTime":"0","summary":"9月8日，苑东生物发布公告称，公司将于9月16日参加科创板2026年半年度创新药行业集体业绩说明会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-08/doc-inircrnn9176436.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-08/doc-inircrnn9176436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688513","BK1574","KSTR","BK1161","BK0239","06978","LNGR","MEDX","159992","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320617","title":"禮邦醫藥-B(09637)：AP308治療IgA腎病的新藥臨床試驗申請獲美國食品藥品監督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320617","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320617?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:03","pubTimestamp":1788869000,"startTime":"0","endTime":"0","summary":"智通财经APP讯，礼邦医药-B 发布公告，公司近日就AP308的新药临床试验申请获美国食品药品监督管理局批准，将启动一项AP308用于治疗IgA肾病的首次人体临床试验。就公司所知，AP308为首个获准开展临床试验的IgA蛋白酶类IgAN候选药物。该平台具有优异的稳定性及成药性，并可在保留蛋白酶对IgA1高效切割活性的同时，显著延长药物体内半衰期、降低肾脏清除并减弱免疫原性，为长效、低频次给药奠定基础。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1161","BK1574","159938","BMED","BK1191","IBBJ","MDTX","159151","BK1515","09637","IBBQ","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103332998","title":"美股盤前｜英特爾、甲骨文升逾4%；諾華重挫12%，IONIS下跌10%；阿斯麥新一代EUV光刻機獲台積電和三星使用承諾","url":"https://stock-news.laohu8.com/highlight/detail?id=1103332998","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103332998?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:01","pubTimestamp":1788868860,"startTime":"0","endTime":"0","summary":"9月8日美元指数上升0.0364%，报98.96。03 要闻1. 三大芯片厂全面采购ASML最先进High NA EUV光刻机以扩产高端制程。ASML确认三星、台积电与英特尔已承诺在2028–2030年起量产使用High NA设备，并与ASML签订光罩尺寸升级合作协议，助力降低AI芯片制造成本。","market":"hk","thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","LU0889566641.SGD","LU2471134879.HKD","BK4526","LU1917777945.USD","BK4612","BK4570","LU1150488218.USD","LU2491049909.HKD","LU1430597077.USD","SPRX","BK4575","IE00BHPRN162.USD","CWI","IYE","LU0432979614.USD","IBB","LU0949170772.SGD","IE00B7SZLL34.SGD","LU0823414478.USD","EGGY","BK4533","INYY","LU0082616367.USD","PJP","SG9999011175.SGD","LU0545039389.USD","LU0345770993.USD","DOG","LU0719512351.SGD","LU1211504680.USD","LU1323610961.USD","LU0211326755.USD","IE00B2Q91V27.USD","LU0158827781.USD","LU1162221912.USD","IE00BZ1G4Q59.USD","BK4588","FTXL","LU0912757837.SGD","PPH","LU2505996509.AUD","BK4538","IE00BMPRXN33.USD","LU2663582299.SGD","ORAC","LU1852331112.SGD","LU0077335932.USD","BK4138","ADVE","LU1548497426.USD","LU1674673428.USD","LU0417517546.SGD","XNTK","FENY","MEDX","BK4592","LU0642271901.SGD","ERX","LU0053666078.USD","LU0433182093.SGD","LU0476273544.USD","TEK","AIQ","03145","LU0878004406.USD","LU2326559502.SGD","LU0170899867.USD","IE000MB6IJN5.SGD","LU1935042991.SGD","LU2322448957.HKD","DRLL","LU1823568750.SGD","LU0795875169.SGD","LU0072462343.USD","LU1235294995.USD","LU0859254822.USD","LU2129689431.USD","CNEQ","BK4512","LU0109394709.USD","LU2211815571.USD","LU1720051017.SGD","IE00B3M56506.USD","LU1815336760.USD","SG9999002521.SGD","LU1061106388.HKD","FCG","LU1674673691.USD","LU1868837565.USD","BK4529","LU0208291251.USD","IEFA","LU2430703095.HKD","AVEM","SG9999004220.SGD","LU0957791311.USD","ORCZ","IE00BFXG0V08.USD","LU0965509283.SGD","LU0882747503.HKD","LU1201861249.SGD","LU2249611893.SGD","BK4550","LU0942090050.USD","LU0070217475.USD","LU2087625088.SGD","LU1093756168.USD","LU2471134952.CNY","SG9999014542.SGD","LU2237957902.USD","IE00BQXX3F31.USD","LU0058720904.USD","LU1732799900.SGD","DBEF","BK4599","LU0300736062.USD","LU0114720955.EUR","LU0496365809.HKD","LU0541502299.USD","TBXU","LU1988902786.USD","LU0225283273.USD","LU2148611432.USD","BK4147","LU0359202008.SGD","LU1778281490.HKD","LU1989764664.SGD","BK4532","LU0612318971.USD","BK4504","CGIC","IE00BQXX3C00.GBP","CHPS","LU0203345920.USD","LU2764263203.CNY","BK4503","BK4579","LU0788109394.HKD","LU1839511570.USD","DRIV","IE000M9KFDE8.USD","LU0353189763.USD","LU1623119135.USD","LU2271345857.HKD","LU2468319806.SGD","IE0031619046.USD","IE00B19Z3581.USD","LU1057294990.SGD","QQQA","LU0823038988.USD","BK4139","LU2298321311.HKD","IE00B775SV38.USD","LU0157215616.USD","LU2491050154.USD","LU0348723411.USD","LU0572940350.SGD","BK4201","LU2462611646.USD","UMMA","PXI","BK4007","ORCL","SGXZ99366536.SGD","LU0654597011.USD","BK4505","LU2746668461.USD","LU0861579265.USD","LU2999663052.SGD","LU1989772923.USD","BK4082","INTW","LU0310799852.SGD","LU0823421416.USD","LU0158827948.USD","LU2471134523.USD","FDTX","FFGX","LU1989764748.USD","LU0345769631.USD","LU0359201612.USD","LU0823434740.USD","LU0128526141.USD","BK4121","IFLR","ORCS",".DJI","ORCX","LU0289739699.SGD","SG9999002224.SGD","LU2242649171.HKD","LU2462591277.SGD","CHAT","BK4097","MEMX","LU2108987350.USD","LU2092937221.SGD","LU2764263039.SGD","LU0868494708.USD","LU1282649810.SGD","LU0130517989.USD","SMH","LU2505996681.GBP","BK4535","LU0345780950.USD","LU1093756325.SGD","LU1815333072.USD","LU2237443978.SGD","LU1037948541.HKD","LU1064131342.USD","VDE","BK4528","LU2471134796.USD","LU1642822529.SGD","LU2931357623.SGD","LU2764262908.HKD","BK4591","SG9999014559.SGD","LU2506952097.USD","SPTE","LU1861220033.SGD","LU0345774631.USD","RSPG","LU2028103732.USD","LU2498475776.HKD","IE00BKVL7J92.USD","GNMX","LU0320765992.SGD","BK7095","IE0034235303.USD","LU1934455194.USD","LU0203347892.USD","LU0122376428.USD","IE0009356076.USD","LU1571399168.USD","LU0648001328.SGD","LU2430703251.USD","IE000BZT7R73.USD","LU0868494617.USD","LU2357125470.USD","LU2324357040.USD","LU2347655156.SGD","LU0211328371.USD","IE00B3CCJ963.GBP","LU2430703178.SGD","LU0345774391.USD","LU2125154935.USD","LU1804176565.USD","LU0444971666.USD","CQTM","IE00BLSP4239.USD","LU1316542783.SGD","CHPX","LU2362541513.USD","LU0823417653.USD","INT","LU1066051498.USD","LU0314106906.USD","AVXC","LU0143551892.USD","LU1506573853.SGD","CGNG","LU2362540622.SGD","PQNT","BK4605","TINS","LU0384037296.USD","LU0072461881.USD","LU0985489474.SGD","LU0124676726.USD","SG9999015358.SGD","LU2089984988.USD","LU0878866978.SGD","LU0094547139.USD","LU2360032135.SGD","LU0359201885.HKD","LU0689626769.HKD","LU0316494557.USD","BK4213","LU0792757196.USD","LU1929549753.HKD","LU1282649067.USD","SG9999001424.SGD","LU2360106780.USD","LU0683600562.USD","HBMX","LU0456854461.SGD","LU2473716301.USD","IE0002270589.USD","LU2272731600.USD","IE00B5949003.HKD","LU0976567544.SGD","LU1508157978.USD","LU1582987324.SGD","SG9999014567.USD","LU2041044095.USD","LU2360108059.USD","LU0823421333.USD","LU2089985449.USD","LU1046421795.USD","LU0210536198.USD","LU2087621335.USD","IE00B7SZL793.SGD","LU0011850046.USD","LU2602419157.SGD","UDOW","LU2106854487.HKD","LU0264606111.USD","LU0553294199.USD","LU0068578508.USD","SG9999001440.SGD","OGIG","IE00BBT3K403.USD","IBBQ","IXC","LU1366192091.USD","LEGR","LU2294711713.HKD","LU0541501648.USD","LU1989771016.USD","LU0787776722.HKD","HYDR","LU2089283258.USD","TDIV","SG9999014575.USD","IE00B5TLWC47.USD","BGIA","IE00BJT1NW94.SGD","LU0648000940.SGD","LU1582986359.USD","LU0572939691.SGD","LU1934455277.USD","CGDG","FENI","CGGO","AIS","IE00BMPRXR70.SGD","LU2211814178.USD","LU0738911758.USD","PBE","LU2054465674.USD","LU0187121727.USD","EPAI","LU1734074674.USD","LU0300736492.USD","ESIM","LU0128525689.USD","IE00BQXX3D17.EUR","LU1935043023.USD","LU2543165471.USD","BK4141","LU0238689110.USD","WEEI","LU0109392836.USD","LU1069347547.HKD","LU2487616109.SGD","XLE","CNAV","LU1267930490.SGD","ORCU","NVS","SG9999015341.SGD","LU0081259029.USD","LU2322448791.USD","LU1023057109.AUD","IE00BFXG1179.USD","LU1691799644.USD","IE00BKDWB100.SGD","LU1732800096.USD","SG9999002232.USD","IE00BZ199S13.USD","LU1153585028.USD","LU0488056044.USD","LU0528227936.USD","LU2242646821.SGD","IE0004091025.USD","LU0823039010.USD","LU0965509010.AUD","LU1037948897.HKD","LU2247934214.USD","LU0477156953.USD","IE00BLSP4452.SGD","LU0149725797.USD","LU0070302665.USD","SPY","LU1935042488.USD","LU2125154778.USD","BAI","BK4515","LU0321505868.SGD","LU0097036916.USD","LU0143863198.USD","LU0868486357.SGD","SPWO","LU1430594728.SGD","BK4543","LU2237443382.USD","LU2290526834.HKD","LU0143863784.USD","LU1435385759.SGD","LU1894683348.USD","LU2236285917.USD","LU0130102774.USD","LU0612318385.USD","LU0345770308.USD","GXPE","LU0320765489.SGD","SGXZ51526630.SGD","IE00BYQQ9H92.USD","LU1974910355.USD","LU0154245673.USD","LU1582986433.USD","LU1074936037.SGD","FOTO","LU2237957811.SGD","LU0310800965.SGD","WUGI","EMM","03165","IE00B2B36J28.USD","BK5113","IE0004086264.USD","BK4578","GSID","FTXN","IE000F7OJYX1.SGD","LU0882574055.USD","BBH","LU0256331488.USD","LU1868837722.USD","IE0009355771.USD","LU0957808578.USD","LU2111349929.HKD","IE00B1XK9C88.USD","LU0154236417.USD","LU1989772840.SGD","IE000SO60NU8.SGD","LU0098860793.USD","LU2129689605.HKD","IE00B66KJ199.SGD","LU2506952170.USD","SGXZ81514606.USD","DDM","LU0950375773.USD","LU2896262040.SGD","LU0323591593.USD","LU0154245756.USD","LU0274383776.USD","LU2506951958.HKD","SG9999013999.USD","LU2357627491.SGD","LU1489326972.SGD","LU0353189680.USD","BK4581","LU0061474960.USD","LU0029874061.USD","LU1935043536.SGD","BK4566","LU2129689514.USD","IGV","LU1003077747.HKD","LU0431992006.USD","QTUP","LU0320765646.SGD","SGXZ57979304.SGD","LU0289960550.SGD","LU1791710582.SGD","IE00BN8TJ469.HKD","DXD","LU0466842654.USD","LU0345769128.USD","LU2133065610.SGD","LU2250418816.HKD","LU0198837287.USD","LU0266512127.USD","LU1718418525.SGD","LU1429558221.USD","BK4023","LU2592432038.USD","LU1934455863.HKD","LU1883866441.USD","LU1035773651.USD","TEXU","SG9999001176.SGD","LU0256863811.USD","LU0661504455.SGD","BK4608","LU2491050071.SGD","BK4157","INTC","LU1150488135.SGD","LU0234570918.USD","EMC","LU0122379950.USD","LU0345781412.USD","BK4527","LU1201861165.SGD","IE00B4R5TH58.HKD","IE00BD6J9T35.USD","LU0266512473.USD","LU0823414551.USD","LU0823417737.USD","LU2237443549.SGD","LU0278409577.USD","CTEX","BK7104","LU1935042215.USD","IE0000B7K699.USD","EFA","LU0251142724.SGD","LU2264538146.SGD","LINT","LU0368265418.SGD","LU2272731865.HKD","LU1803068979.SGD","LU2272731782.SGD","BK4534","LU0084288322.USD","BK4170","LU1712237335.SGD","LU1048588211.SGD","BK4559","LU0211331839.USD","LU0056508442.USD","IE00BSNM7G36.USD","LU2023251221.USD","LU2720916845.USD","LU2102340556.USD","HK0000304805.HKD","BIB","THNR","LU0878005551.USD","SG9999001176.USD","LU2244417387.USD","LU2112291526.USD","BK4548","LU0980610538.SGD","CRAK","LU1992135472.HKD","TRUN","LU2265009873.SGD","OZEM","LU1992135399.USD","LU0267386448.USD","IEO","LU0795875086.SGD","BK4148","IE0004445239.USD","LU0175139822.USD","LU1267930813.SGD","LU2360107168.USD","KNOW","LU1720051108.HKD","LU1582987597.SGD","IE00BMPRXQ63.HKD","LU0234572021.USD","LU1868838027.USD","LU2746668974.SGD","LU0251132253.USD","LU0211326839.USD","PXE","BK4585","IE00BFTCPJ56.SGD","IGE","SG9999003800.SGD","LU0052756011.USD","LU0823434583.USD","WQTM","LUMA","TNGY","LU0130103400.USD","LU0742534661.SGD","LU2860962120.EUR","ASIA","LU2362541273.HKD","LU1983299246.USD","LU2237443622.USD","IE00BKPKM429.USD","SDOW","ILOW","LU0889565833.HKD","IE000WAW04H5.SGD","LU0266013472.USD","LU2506951875.HKD","DBEU","LU0138981039.USD","LU0211327993.USD","LU1366333091.USD","CORO","IE00B1BXHZ80.USD","LU0965509101.SGD","TTEQ","IE00B19Z3B42.SGD","LU2242652126.USD","LU0210528500.USD","LU2458330243.SGD","LU2750360641.GBP","LU2063271972.USD","LU2458330169.SGD","BK4602","BLOX","SOXX","LU0630314457.HKD","IE00BGHQF524.EUR","IE00B3S45H60.SGD","IE00B19Z4B17.USD","LU0444973449.USD","LU0251131958.USD","LU0321505439.SGD","LU2750360997.AUD","BK4516","LU0048573561.USD","LU1066053197.SGD","LU0965508806.USD","HK0000304797.USD","LU0889565916.HKD","BK4554","AVSE","OILT","LU0048584097.USD","LU0823416689.USD","LU1023059063.AUD","LU2023250504.SGD","LU2506951792.HKD","LU2357305700.SGD","LU2954938101.SGD","DIG","SG9999000418.SGD","GNOM","LU1291159041.SGD","IE0002141913.USD","LU1585245621.USD","LU2089284900.SGD","LU1791710400.SGD","LU1894683264.USD","DIA","LU0162691827.USD","ASMH","LU1861215975.USD","IE00BWXC8680.SGD","LU1267930227.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320908","title":"AI 製藥迎來價值兑現期，創新藥產業打開全新增長空間","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320908","media":"独角兽智库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320908?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 19:44","pubTimestamp":1788867840,"startTime":"0","endTime":"0","summary":"AI 制药行业已经走过早期概念炒作阶段，产业验证层级持续向上，从算法叙事正式转向管线价值兑现，行业商业化拐点正在加速到来。随着 AI 制药行业持续发展，生物测序数据需求持续扩张，设备与试剂业务打开增量空间，站在产业链上游充分受益行业整体景气上行。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-08/doc-inircmes6042281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","IBBQ","VTHR","BK1191","06978","LNGR","AIPO","ARTY","QTOC","01477","BK1161","AGIX","CHAT","159992","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665324003","title":"PHARVARIS的3期臨床試驗達到全部主要及次要終點。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665324003","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665324003?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 18:53","pubTimestamp":1788864791,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MDTX","IBBJ","PSYK","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329150","title":"石藥集團：SYH2083滴眼液獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329150","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329150?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:51","pubTimestamp":1788861091,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","IBBJ","IBBQ","BMED","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329827","title":"膽固醇藥物臨床試驗受挫，數十億美元研發競賽蒙上陰影","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329827","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329827?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:33","pubTimestamp":1788859980,"startTime":"0","endTime":"0","summary":"受该消息影响，诺华周一股价下跌 3%。诺华表示完整试验结果将在后续医学学术大会上公布。诺华强调，本次 8000 多名受试者均已接受最优标准治疗。诺华失利，安进与礼来压力陡增此前分析师测算，如果 pelacarsen 临床试验成功，其销售峰值有望达到每年 4050 亿美元。但该临床试验的冲击不止波及诺华一家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-08/doc-inirceww4625928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MDTX","IBBJ","IBBQ","BMED","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665215326","title":"諾華試驗受挫且BMO下調評級，安進股價下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2665215326","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665215326?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:27","pubTimestamp":1788859661,"startTime":"0","endTime":"0","summary":"BUZZ-诺华试验受挫且BMO下调评级，安进股价下跌9月8日-** 安进公司（AMGN.O）股价盘前下跌4.8%，至416美元** 诺华公司（NOVN.S）的降胆固醇药物在一项备受关注的研究中未能达标，这引发了市场对安进公司（Amgen）实验性降胆固醇药物olpasiran的担忧 (link)** 摩根大通分析师表示，诺华的pelacarsen研究结果降低了市场对安进olpasiran的预期，而该","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4T4500MM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","IE00BJJMRZ35.SGD","LU1061106388.HKD","LU0058720904.USD","SG9999001440.SGD","BK4581","BK4588","IBBQ","LU0889565916.HKD","IE00BFTCPJ56.SGD","BIB","PBE","LU0109394709.USD","LU0122379950.USD","BK4139","LU0320765992.SGD","LU1983299246.USD","IE0009355771.USD","LU1057294990.SGD","BK4534","LU2112291526.USD","LU1023059063.AUD","IE00B2B36J28.USD","BK4533","LU2089984988.USD","BK4599","LU2242652126.USD","AMGN","BBH","LU1571399168.USD","IBB","IE00BJT1NW94.SGD","LU0289739699.SGD","IE0002141913.USD","LU2242646821.SGD","LU0868494617.USD","BK4566","LU2468319806.SGD","PJP","IE00B4R5TH58.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665132698","title":"復星醫藥(600196.SH)子公司FXS5626片獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665132698","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665132698?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:13","pubTimestamp":1788858794,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复星医药产业发展有限公司收到国家药品监督管理局关于同意FXS5626片用于治疗非节段型白癜风开展II/III期适应性无缝设计临床试验的批准。复星医药产业拟于条件具备后于中国境内开展该药品的相关临床研究。截至2026年8月，公司现阶段针对FXS5626的累计研发投入约为1.08亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","IBBQ","BK1191","BK0028","IBBJ","BK0196","BK0175","BK1515","600196","BK0012","BK0187","02196","BMED","PSYK","BK0183","BK0060","BK1593","BK0096","BK0239","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176595225","title":"盤前異動：安進、耐克、Bloom Energy 等個股受關注","url":"https://stock-news.laohu8.com/highlight/detail?id=1176595225","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176595225?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:10","pubTimestamp":1788858632,"startTime":"0","endTime":"0","summary":"安进：这家生物科技巨头、道琼斯指数的重要权重股，其盘前股价重挫逾5%。此前，瑞士制药商诺华宣称，其一款实验性药物在晚期临床试验中未能有效降低心血管风险。安进与礼来目前正在各自研发竞品疗法以应对挑战。消息传出后，诺华在欧股市场大跌10%，礼来股价亦小幅走低。Bloom Energy：这家燃料电池制造商可谓利好连连。受此提振，其盘前股价上扬4%。游戏驿站定于今日美股收盘后发布财报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","APED","BK4539","BK4566","BK4535","BK4182","BIB","BKCH","VCLN","BK4547","LU2264538146.SGD","HOOW","BK4595","SMI3.UK","LU0792757196.USD","BK4578","LU0310800965.SGD","LU1642822529.SGD","COIN","BK4596","LU2098885051.SGD","BEX","IBBQ","IE00B4R5TH58.HKD","IBAT","SMST","BK4533","BK4561","LU0823414551.USD","GMEC","IBLC","LU1861558580.USD","07799","LU0029864427.USD","LU1267930813.SGD","MSTW","STYL","CONL","SIMS","BK4541","IGME","LU2360107671.USD","MSTK","LU0058720904.USD","LU0823414478.USD","LU1303367103.USD","IE00B2B36J28.USD","WATS","09399","BITQ","CRPT","LU1023059063.AUD","LU1861217088.USD","LU1861220207.SGD","MSTR","EGGY","BK4585","LU0444971666.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","UPGR","CTEC","NVS","MSDD","BEG","3SMI.UK","LU0289739699.SGD","IE0009355771.USD","07711","BK4599","BPAY","LU1571399168.USD","SG9999001440.SGD","SMOG","MSTP","HOOG","LU2112291526.USD","FIAT","IBB","FDIG","BK4139","IMST","LU1983299246.USD","BK4146","COYY","LU0786609619.USD","BK4581","04332","COIO","BK4600","LU2089984988.USD","CONI","BK4558","WNTR","LU2294711713.HKD","CONX","BEC","LU1057294990.SGD","MSTX","LU0708994859.HKD","COIA","HOOD","LU2506951792.HKD","CONY","ICLN","MSOO","AMGN","BBH","ICOI","COIX","HOOZ","LU0957808578.USD","09799","GMEY","LU2468319806.SGD","ROBN","IE00BYQQ9H92.USD","COIW","BK4554","CNRG","BK4534","HOOI","BK4007","BK4076","GMEU","GME","LU0211331839.USD","BK4588","LU0109394709.USD","LU0128525689.USD","FRNW","LU2242646821.SGD","LU1267930227.SGD","LU0070302665.USD","HOOX","PBE","HOOC","07399","MSTY.UK","IE0009354923.USD","IE00BJT1NW94.SGD","3LMI.UK","07311","MSTZ","09311","LU1064131342.USD","TBXU","LU0052756011.USD","PJP","MST","LU2357125470.USD","LU0310800379.SGD","LU2242652126.USD","LU1267930573.SGD","BK4023","MSTC","LU0823411888.USD","MSST","LU2249611893.SGD","BEZ","09711","MSTU","LMI3.UK","VTWG","IAI","LU0320765489.SGD","HOOY","MSII","LU0476273544.USD","BK4551","COIG","IE0002141913.USD","LU0208291251.USD","HODU","HOYY","LU1061106388.HKD","LU0320765992.SGD","MEDX","ZAP","BK4112","LU2543165471.USD","MSTY","DAPP","LU0889565916.HKD","LU1988902786.USD","LU1815336760.USD","BLCK","NKE","IE00BFXG0V08.USD","LU0128525929.USD","LU0868494617.USD","COII","BK4127","FINX","BK4532","PPH","OWNB","LU0122379950.USD","LU0444973449.USD","MTYY","HOII","LU1861559042.SGD","BK4577","LU0889566641.SGD","BE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665326953","title":"美股異動｜安進盤前跌5.4%，諾華同靶點藥物III期臨床失敗，Lp(a)賽道遭重創","url":"https://stock-news.laohu8.com/highlight/detail?id=2665326953","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665326953?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:07","pubTimestamp":1788858422,"startTime":"0","endTime":"0","summary":"消息面上，诺华于9月4日公布，其与Ionis联合开发的降脂药物Pelacarsen，在名为LpHORIZON的III期临床试验中未能达到主要终点。诺华的Pelacarsen是全球首个针对Lp靶点进行心血管结局验证的III期药物。因此，市场担忧情绪蔓延到了同样在开发Lp药物的安进身上。多家分析机构认为，诺华的失败削弱了但并未完全推翻Lp这一靶点的可行性。安进后续公布的Olpasiran完整试验数据，将成为判断该靶点未来走向的关键。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/08/20260908512020.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/08/20260908512020.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260908/32363493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4599","BK4139","BK4566","LU0058720904.USD","BK4532","IE00BFTCPJ56.SGD","LU2112291526.USD","AMGN","BK4588","BK4585","LU1983299246.USD","BBH","LU0109394709.USD","PPH","PJP","LU2468319806.SGD","IE0002141913.USD","LU1023059063.AUD","IE00BJJMRZ35.SGD","TBXU","LU0070302665.USD","LU0868494617.USD","BK4534","MEDX","PBE","LU2242652126.USD","IBB","LU0208291251.USD","LU0320765489.SGD","LU1057294990.SGD","BK4007","IBBQ","IE00B4R5TH58.HKD","BK4581","LU2089984988.USD","BK4578","LU0122379950.USD","IE0009355771.USD","BK4533","LU0889565916.HKD","LU0320765992.SGD","LU0211331839.USD","BIB","SG9999001440.SGD","NVS","LU0289739699.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU1061106388.HKD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665257563","title":"製藥巨頭諾華股價大跌近10%，遭遇三項藥物臨床試驗受挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2665257563","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665257563?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:50","pubTimestamp":1788857448,"startTime":"0","endTime":"0","summary":"该股最新跌幅达 9.4%。一周之内接连遭遇第三起临床试验挫折，引发投资者抛售，股价或将创下上市以来最差单日交易记录。德尔德西兰临床试验失利数日之前，诺华另一款用于降低心血管事件风险的药物刚在晚期临床试验遇挫；一周前，诺华还宣布，因三名受试者死亡，暂停了实验性细胞疗法 rapcel 的八项临床试验。","market":"us","thumbnail":"http://n.sinaimg.cn/finance/transform/59/w550h309/20260908/d06c-43061a4fc4516fcb77a4d9ff51620de1.png","type":0,"news_type":0,"thumbnails":["http://n.sinaimg.cn/finance/transform/59/w550h309/20260908/d06c-43061a4fc4516fcb77a4d9ff51620de1.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-08/doc-inirceww4608579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["BK4588","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","IE0002141913.USD","BK4007","IBBJ","PSYK","LU0320765489.SGD","MDTX","IBBQ","BK4578","NVS","IE0009355771.USD","MEDX","BK4585","LU0211331839.USD","PPH","LU0208291251.USD","BMED","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0070302665.USD","IE00BFTCPJ56.SGD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665258833","title":"安進股價盤前下跌5.4%；競爭對手諾華的膽固醇藥物後期臨床試驗失敗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665258833","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665258833?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:28","pubTimestamp":1788856084,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["TBXU","LU0289739699.SGD","BK4533","BK4585","BK4578","BK4534","BK4007","IE00BJJMRZ35.SGD","LU0070302665.USD","IBB","LU1061106388.HKD","LU2112291526.USD","LU2242652126.USD","PBE","PJP","LU1983299246.USD","BK4588","IE00BFTCPJ56.SGD","BIB","LU1023059063.AUD","IE0002141913.USD","BK4599","BK4532","BBH","LU0211331839.USD","LU0320765992.SGD","PSYK","MDTX","LU0122379950.USD","LU0868494617.USD","SG9999001440.SGD","LU0058720904.USD","LU0889565916.HKD","MEDX","LU0208291251.USD","IBBJ","LU0109394709.USD","IBBQ","AMGN","IE00BJT1NW94.SGD","NVS","LU0320765489.SGD","PPH","LU2242646821.SGD","BMED","BK4581","LU1057294990.SGD","LU2089984988.USD","LU2468319806.SGD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":9,"totalSize":213,"code":"91000000","status":"200"}]}}